Detail akcie Oncology Inst Rg online

Business Summary: Starling Oncology, Inc., formerly The Oncology Institute, Inc., is advancing oncology by delivering specialized, value-based cancer care in the community setting. The Company offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with oncology organizations. Its critical services include cancer treatment and infusion centers, in-house dispensary, lab testing, outpatient blood transfusion, financial counseling, end-of-life counseling and comprehensive clinical trials. It treats many forms of cancer, including Acute lymphoblastic leukemia; Acute myeloid leukemia; Bladder cancer; Bone cancer; Brain cancer; Cervical cancer; Choriocarcinoma; Chronic lymphocytic leukemia (CLL); Chronic myeloid leukemia (CML); Skin cancer, and others. It operates over 100 clinics and affiliate locations across multiple states.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Starling Oncology, Inc. revenues increased 38% to $308.7M. Net loss applicable to common stockholders decreased 66% to $10.3M. Revenues reflect Specialty pharmacy segment increase of 78% to $87.5M, Dispensary segment increase of 58% to $98.6M. Lower net loss reflects Fair Value Adjustments on Other Asse increase from $7.3M (expense) to $1.8M (income).